Reducing the risk of metastatic relapse in patients with resectable soft tissue sarcomas is crucial for improving outcomes, because metastasis is the primary cause of mortality in this population.
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...
INAVO120 clinical trial evaluated 325 patients, who were randomly assigned with Inavolisib or placebo plus palbociclib and fulvestrant. The primary endpoint was progression free survival (PFS), and ...
improved patient outcomes-;particularly survival-;are the key determinant, said John Fox, senior director of Market Access at Illumina. "These real-world results across multiple solid tumor types ...
Global Breast Cancer Screening Tests Market was valued at approximately USD 2.93 billion in 2023 and is projected to grow with a healthy CAGR of 54.3% over the forecast period 2024-2032. Read the ...
The 2-year progression free survival was improved with the addition of toripalimab (92·0% [95% CI 86·7–97·3]) compared with placebo (74·0% [61·8–86·2]; stratified hazard ratio 0·40 [95% CI 0·18–0·89]; ...
The findings point to the critical role of community, mutual and familial support networks as essential survival strategies. However, these social networks are also increasingly depleted, revealing ...